2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 1448

Clinical Impact of Articular Ultrasound in Diagnosis and Follow-up of Patients with Polyarthritis

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1493

Clinical Predictor Factors Associated with Sustained Disease Activity Among Patients with Early Rheumatoid Arthritis

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1450

Clinical Radiology Reports Are Unreliable for Assessment of Radiographic Structural Progression in US Veterans with Rheumatoid Arthritis Initiating Tumor Necrosis Factor Inhibitor Therapy

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1776

Clinical Significance of Allergy in IgG4-Related Disease

Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1704

Clinical SLE Disease Activity Index Score of Zero May be a More Pragmatic Outcome Measure in SLE Studies

Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 1570

Clinical Utility of a Second Minor Salivary Gland Biopsy in Patients with Suspected Sjögren’s Syndrome: A Retrospective Cohort Study

Sjögren's Syndrome – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 1318

Clinical Utility of Ultrasonography (US) in Diagnosing and Monitoring Disease Activity of Relapsing Polychondritis (RP) and Comparison of Cartilaginous US Findings between RP, Repeated Trauma and Healthy Subjects

Miscellaneous Rheumatic and Inflammatory Diseases Poster II: Interstitial Lung Disease, Still's Disease, FMF, Polychondritis

9:00AM-11:00AM: Abstract Number: 1649

Cohort Identification of Axial Spondyloarthritis in a Large Healthcare Dataset: Current and Future Methods

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1329

Combination of Methotrexate and Leflunomide in Refractory Chronic Adult Onset Still’s Disease: Case Series and Literature Review

Miscellaneous Rheumatic and Inflammatory Diseases Poster II: Interstitial Lung Disease, Still's Disease, FMF, Polychondritis

9:00AM-11:00AM: Abstract Number: 1452

Combination of Ultrasound Power Doppler-Verified Synovitis and Seropositivity Accurately Identifies Patients with Early Rheumatoid Arthritis

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1089

Commensal Gut Bacteria of Anti-Ro Positive Mothers of Children with Neonatal Lupus in Aggregate Resemble Healthy Subjects without Overt Dysbiosis of Abundance of Microorganisms

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1565

Comorbidity Burden in Primary Sjögren’s Syndrome: A Long-Term Observation in Clinical Practice

Sjögren's Syndrome – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 1098

Comparative Analysis of the Total Proteome of the Skin Lesions from Cutaneous Lupus Erythematosus (CLE) and Dermatomyositis (DM)

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1174

Comparative Cost per Response for Four Clinical Outcomes of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial in Patients with Rheumatoid Arthritis

Health Services Research Poster II – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 1615

Comparative Risk of Atrial Fibrillation and Cardiovascular Events between TNF-Inhibitors and Ustekinumab in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].